Lab21 hires cfo

Susan Lowther joins Cambridge, UK-based firm

Lab21, a Cambridge, UK-based specialist in personalised medicine, has hired Susan Lowther as chief financial officer.

Lowther has spent more than 20 years in the pharmaceutical, biotech and healthcare industries and has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.

Graham Mullis, Lab21 ceo, said: ‘Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company.’

You may also like

Research & Development

Lab21 sells South Carolina laboratory operations

Will continue to focus on diagnostic content opportunities within the US market
Finance

Lab21 acquires Myconostica

Expands growing proprietary diagnostic portfolio
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Finance

Lonza to expand bioscience testing offering with the acquisition of Redberry

Acquisition to include Red One solid-phase cytometry platform for rapid sterility and bioburden testing, which expands Lonza’s portfolio of automated, scalable solutions for pharmaceutical quality control (QC)
Finance

Shilpa Medicare opens flow chemistry manufacturing centre

The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.
Subscribe now